Literature DB >> 32145315

The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease.

Almira Kurbegovic1, Marie Trudel2.   

Abstract

The transcription factors Myc and p53 associated with oncogenesis play determinant roles in a human genetic disorder, autosomal dominant polycystic kidney disease (ADPKD), that was coined early in ADPKD etiology a «neoplasia in disguise ». These factors are interdependent master cell regulators of major biological processes including proliferation, apoptosis, cell growth, metabolism, inflammation, fibrosis and differentiation that are all modulated in ADPKD. Myc and p53 proteins evolved to respond and carry out overlapping functions via opposing mechanisms of action. Studies in human ADPKD kidneys, caused by mutations in the PKD1 or PKD2 genes, reveal reduced p53 expression and high expression of Myc in the cystic tubular epithelium. Myc and p53 via direct interaction act respectively, as transcriptional activator and repressor of PKD1 gene expression, consistent with increased renal PKD1 levels in ADPKD. Mouse models generated by Pkd1 and Pkd2 gene dosage dysregulation reproduce renal cystogenesis with activation of Myc expression and numerous signaling pathways, strikingly similar to those determined in human ADPKD. In fact, upregulation of renal Myc expression is also detected in virtually all non-orthologous animal models of PKD. A definitive causal connection of Myc with cystogenesis was established by renal overexpression of Myc in transgenic mice that phenocopies human ADPKD. The network of activated signaling pathways in human and mouse cystogenesis individually or in combination can target Myc as a central node of PKD pathogenesis. One or many of the multiple functions of Myc upon activation can play a role in every phases of ADPKD development and lend credence to the notion of "Myc addiction" for cystogenesis. We propose that the residual p53 levels are conducive to an ADPKD biological program without cancerogenesis while a "p53 dependent annihilation" mechanism would be permissive to oncogenesis. Of major importance, Myc ablation in orthologous mouse models or direct inhibition in non-orthologous mouse model significantly delays cystogenesis consistent with pharmacologic or genetic inhibition of Myc upstream regulator or downstream targets in the mouse. Together, these studies on PKD proteins upon dysregulation not only converged on Myc as a focal point but also attribute to Myc upregulation a causal and « driver » role in pathogenesis. This review will present and discuss our current knowledge on Myc and p53, focused on PKD mouse models and ADPKD.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Mouse models; Myc addiction; Polycystin; Renal development; p53-dependent annihilation

Mesh:

Substances:

Year:  2020        PMID: 32145315     DOI: 10.1016/j.cellsig.2020.109594

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  10 in total

Review 1.  Normal and Neoplastic Growth Suppression by the Extended Myc Network.

Authors:  Edward V Prochownik; Huabo Wang
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

2.  Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Lauren Pickel; Ioan-Andrei Iliuta; James Scholey; York Pei; Hoon-Ki Sung
Journal:  Adv Nutr       Date:  2021-11-10       Impact factor: 8.701

3.  Small hairpin inhibitory RNA delivery in the metanephric organ culture identifies long noncoding RNA Pvt1 as a modulator of cyst growth.

Authors:  Kara Eckberg; Ivan Weisser; Daniel Buttram; Nikunj Somia; Peter Igarashi; Karam S Aboudehen
Journal:  Am J Physiol Renal Physiol       Date:  2022-07-21

4.  Value of serum p53, PKD1, and MAP2K4 in evaluating the condition and prognosis of endometrial carcinoma.

Authors:  Xiang Zhang; Yue Huang; Xuecheng Pang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

5.  A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease.

Authors:  Harini Ramalingam; Sonu Kashyap; Patricia Cobo-Stark; Andrea Flaten; Chun-Mien Chang; Sachin Hajarnis; Kyaw Zaw Hein; Jorgo Lika; Gina M Warner; Jair M Espindola-Netto; Ashwani Kumar; Mohammed Kanchwala; Chao Xing; Eduardo N Chini; Vishal Patel
Journal:  Cell Metab       Date:  2021-04-13       Impact factor: 31.373

Review 6.  Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.

Authors:  Sarah K Madden; Aline Dantas de Araujo; Mara Gerhardt; David P Fairlie; Jody M Mason
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

7.  NS398 as a potential drug for autosomal-dominant polycystic kidney disease: Analysis using bioinformatics, and zebrafish and mouse models.

Authors:  Sixiu Chen; Linxi Huang; Shoulian Zhou; Qingzhou Zhang; Mengna Ruan; Lili Fu; Bo Yang; Dechao Xu; Changlin Mei; Zhiguo Mao
Journal:  J Cell Mol Med       Date:  2021-09-22       Impact factor: 5.310

Review 8.  Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches.

Authors:  Carla Navarro; Ángel Ortega; Raquel Santeliz; Bermary Garrido; Maricarmen Chacín; Néstor Galban; Ivana Vera; Juan Bautista De Sanctis; Valmore Bermúdez
Journal:  Pharmaceutics       Date:  2022-06-19       Impact factor: 6.525

Review 9.  Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.

Authors:  Xia Zhou; Vicente E Torres
Journal:  Front Mol Biosci       Date:  2022-09-02

10.  Effect of Reducing Ataxia-Telangiectasia Mutated (ATM) in Experimental Autosomal Dominant Polycystic Kidney Disease.

Authors:  Jennifer Q J Zhang; Sayanthooran Saravanabavan; Gopala K Rangan
Journal:  Cells       Date:  2021-03-03       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.